No

Immune Globulin

Provide prophylactic passive immunity to hepatitis B infection to those individuals exposed; newborns of mothers known to be hepatitis B surface antigen positive; hepatitis B immune globulin is not indicated for treatment of active hepatitis B infections and is ineffective in the treatment of chronic active hepatitis B infection

C

Hypersensitivity to hepatitis B immune globulin or any component; allergies to gamma globulin or anti-immunoglobulin antibodies; allergies to thimerosal; IgA deficiency; I.M. injections in patients with thrombocytopenia or coagulation disorders

1% to 10%:

Central nervous system: Dizziness, malaise

Dermatologic: Urticaria, angioedema, rash, erythema

Local: Pain and tenderness at injection site

Neuromuscular & skeletal: Arthralgia

<1%: Anaphylaxis

Interferes with immune response of live virus vaccines

Refrigerate at 2°C to 8°C (36°F to 46°F); do not freeze

Hepatitis B immune globulin (HBIG) is a nonpyrogenic sterile solution containing 10% to 18% protein of which at least 80% is monomeric immunoglobulin G (IgG). HBIG differs from immune globulin in the amount of anti-HB_s. Immune globulin is prepared from plasma that is not preselected for anti-HB_s content. HBIG is prepared from plasma preselected for high titer anti-HB_s. In the U.S., HBIG has an anti-HB_s high titer >1:100,000 by IRA. There is no evidence that the causative agent of AIDS (HTLV-III/LAV) is transmitted by HBIG.

Absorption: Slow

Time to peak serum concentration: 1-6 days

I.M.:

Adults: Postexposure prophylaxis: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); usual dose: 3-5 mL; repeat at 28-30 days after exposure

Note: HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response

Administration of HBIG preceding or concomitantly with hepatitis B vaccine does not interfere with the immune response to vaccine; the two together provide more rapid protective antibodies to hepatitis B than when vaccine is used alone; rapid levels may be necessary in certain settings

No information available to require special precautions

No effects or complications reported

Be aware of adverse effects

I.M. injection only; to prevent injury from injection care should be taken when administering to patients with thrombocytopenia or bleeding disorders; do not administer I.V.

Injection:

HyperHep®: 0.5 mL, 1 mL, 5 mL